Comparative Pharmacology
Head-to-head clinical analysis: AMANTADINE versus BKEMV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMANTADINE versus BKEMV.
AMANTADINE vs BKEMV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amantadine is an antiviral and antiparkinsonian agent. Its antiviral mechanism involves inhibition of viral uncoating, thereby blocking influenza A M2 ion channel. In Parkinson's disease, it is thought to increase dopamine release and inhibit its reuptake, and may also have anticholinergic and NMDA receptor antagonist effects.
BKEMV is a monoclonal antibody that binds to the extracellular domain of the HER2/neu receptor, inhibiting downstream signaling pathways including PI3K/Akt and MAPK, thereby reducing cell proliferation and promoting antibody-dependent cell-mediated cytotoxicity (ADCC).
100 mg orally twice daily for Parkinson's disease; 100 mg orally twice daily for influenza A prophylaxis/treatment (up to 200 mg/day).
Intravenous: 100 mg every 12 hours; oral: 50 mg twice daily.
None Documented
None Documented
Clinical Note
moderateAmantadine + Haloperidol
"The therapeutic efficacy of Haloperidol can be decreased when used in combination with Amantadine."
Clinical Note
moderateAmantadine + Mifepristone
"Amantadine may increase the QTc-prolonging activities of Mifepristone."
Clinical Note
moderateAmantadine + Promazine
"The therapeutic efficacy of Promazine can be decreased when used in combination with Amantadine."
Clinical Note
moderateAmantadine + Chlorpromazine
Terminal elimination half-life: 10-14 hours in young adults, up to 24 hours in elderly; prolonged to >24 hours in renal impairment
Terminal elimination half-life: 12-18 hours in healthy adults; prolonged in renal impairment (up to 30 hours in CrCl <30 mL/min).
Renal: 90% as unchanged drug via glomerular filtration and tubular secretion; fecal: <10%
Renal excretion: 40-50% unchanged; biliary/fecal: 20-30% as metabolites; total clearance approximates renal clearance.
Category C
Category C
Antiviral / Antiparkinsonian
Antiviral, HIV
"The therapeutic efficacy of Chlorpromazine can be decreased when used in combination with Amantadine."